Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price176.02 USD
Fair value260.63
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Distribution176.83-0.5% to today ✓Markdown gives way to Distribution after an 11% slide in 4 weeks
2026-10-02Read Markdown197.66-10.9% to today ✓Distribution gives way to Markdown after a 15% slide in 6 weeks
2026-08-23Read Distribution233.55-24.6% to today ✓Markup gives way to Distribution after an 11% slide in 7 weeks
2026-07-02Read Markup261.32-32.6% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bel Fuse Inc. holds its Distribution at $176.02. The statistical read favours the sellers, held for 37 days.
As held on the ledger · 2026-10-27
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 37 days
Price at the screen
$176.02
Valuation
43.23 trailing · 22.08 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.37
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.67%
Below 33%
Interest-bearing debt is just 23.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
19.17%
Below 49%
Money owed to the company is 19.2% of assets, under the 49% limit.
Pass
Revenue purity
0.15%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Bel Fuse clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BELFA's ethical verdict changes
Today BELFA passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 47.4% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus None. The average target sits +78% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Component Maker Sits in No Man's Land
Picture a factory floor turning out power modules and connectors for servers and cars. Bel Fuse does exactly that, yet its 17% revenue growth and 8% profit margin land it nowhere near our opportunity screen despite a 23% gap to fair value. The 24.7 times forward earnings price already bakes in decent execution, leaving little room for the unknown moat to matter.
The single analyst target of 322 dollars offers thin comfort when return on equity sits at just 14% and the business shows no standout edge versus larger peers. Ethical clearance removes one objection, but the plain numbers still fail to clear our bar for conviction.
Cyclical demand swings in electronics and limited scale keep downside risk real even at today's price. A modest slip in orders would erase the apparent safety margin quickly. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BELFA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$176.83+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$176.83+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$176.83+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$176.83+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$176.83+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$176.83+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$176.77-9.5%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Markdown$195.38-1.2%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 45% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322.
2026-10-02Markdown · changed$197.66-15.4%Entry 6
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 45% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 253%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (1 analysts) rates it none, with a mean price target of $322.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
